The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion and recommended granting marketing authorization for Tabrecta (capmatinib) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer harboring alterations leading to mesenchymal-epithelial-transition factor gene exon 14 (METex14) skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Portage Biotech Inc., NCI, and Stimunity entered a Cooperative Research and Development Agreement, under which they will collaborate with NCI’s Center for Cancer Research to advance preclinical and potential clinical development of STING agonists and anti-Receptor for Advanced Glycation End products (RAGE) agents to enhance the efficacy of cancer vaccines developed in the NCI CCR Vaccine Branch.
FDA granted clearance to version 1.1 of the next generation SmartFrame Array Neuro Navigation System and Software, sponsored by ClearPoint Neuro Inc.
William L. Dahut, the NCI clinical director, was named chief scientific officer of the American Cancer Society.
Professional societies are implementing measures to limit transmission of SARS-CoV-2 at conferences, as oncology groups reconvene in-person annual meetings for the first time since early 2020. The American Society of Clinical Oncology will require proof of vaccination, encourage indoor masking, and provide masks onsite—regardless of mandates and regulations—at its upcoming annual meeting June 3-7 in... […]
It’s no secret that cancer center marketing and communications has changed drastically over the past 20 years. With the evolution of consumerism and managed care, the immense growth in scope and scale of cancer center activities and the ever-growing dominance of digital marketing and communications is increasingly integral to the work of cancer center executives as they advance patient care and research and boost the bottom lines of even health systems and parent institutions. The NCI Public Affairs & Marketing Network (PAMN) has been a key player and partner through it all.
Break Through Cancer announced $50 million in grants to support research projects using a “TeamLab” structure—designed to maximize interdisciplinary collaboration among researchers at Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, Koch Institute for Integrative Cancer Research at MIT, and The University of Texas MD Anderson Cancer Center.
J. Paul Taylor was named scientific director and executive vice president of St. Jude Children’s Research Hospital. Taylor will replace Jim Morgan, who served as scientific director and executive vice president from 2015-22. Morgan is retiring from his position as scientific director.
Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine established the Sylvester Pancreatic Cancer Research Institute. The center will support research, increase collaborations between scientists and clinicians, and provide more treatment and clinical trial opportunities for patients.
A gift commitment of $12.5 million to Indiana University School of Medicine from the Vera Bradley Foundation for Breast Cancer will support research in immunotherapy for triple negative breast cancer.
